In an evolution of the cGMP methods for the expansion of TIL for the treatment of cancer that the researchers employ in a currently active human clinical trial27, we sought to develop an adoptive T cell therapy for COVID-19 based on rapid ex vivo expansion of SARS-CoV-2 antigen-specific VIL. Here, VIL1 is linked to COVID-19.